Halozyme Therapeutics (HALO) Operating Income (QoQ) (2010 - 2026)
Halozyme Therapeutics (HALO) Operating Income (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Halozyme Therapeutics | 9.71 Bn | 9.40 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 298.64% |
| Dec 31, 2025 | -142.63% |
| Sep 30, 2025 | 7.65% |
| Jun 30, 2025 | 43.03% |
| Mar 31, 2025 | -19.35% |
| Dec 31, 2024 | 7.54% |
| Sep 30, 2024 | 39.21% |
| Jun 30, 2024 | 22.71% |
| Mar 31, 2024 | -5.44% |
| Dec 31, 2023 | 14.45% |
| Sep 30, 2023 | -6.54% |
| Jun 30, 2023 | 75.57% |
| Mar 31, 2023 | -27.79% |
| Dec 31, 2022 | -10.54% |
| Sep 30, 2022 | 144.54% |
| Jun 30, 2022 | -54.99% |
| Mar 31, 2022 | 33.85% |
| Dec 31, 2021 | -25.21% |
| Sep 30, 2021 | -18.77% |
| Jun 30, 2021 | 83.40% |